Stopped: lack of funding
The purpose: To determine the safety and efficacy of Radiofrequency Ablation (RFA) HALO Ultra system in patients with Gastric Antral Vascular Ectasia patient cohort (GAVE). Research design: This is a prospective observational study. Procedure Used: Radiofrequency Ablation Risks and potential benefits: There are no risks associated with this study as it is a retrospective chart review. Potential benefits include the knowledge gained from this study which may be of help to patients in the future. Importance of knowledge that may reasonably be expected to result The knowledge gained from this study may be of help to other patients in the future.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of RFA therapy sessions with the HALO ULTRA device
Timeframe: Up to 1 year after first RFA session with the HALO ULTRA device
Hemoglobin level
Timeframe: Before the first RFA session with HALO ULTRA device.
Hemoglobin level
Timeframe: At the time of resolution of GAVE lesions, which is up to 1 year after first RFA session with HALO ULTRA device.
Number of patients who require blood transfusion
Timeframe: Before the first RFA session with HALO ULTRA device
Number of patients who require blood transfusion
Timeframe: At the time of resolution of GAVE lesions, which is up to 1 year after first RFA session with HALO ULTRA device.